# A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

> **NCT04880876** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **AbbVie** · enrollment: 124 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** 25mg Eluxadoline
- **DRUG:** 100mg Eluxadoline

## Key facts

- **NCT ID:** NCT04880876
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-08-13
- **Primary completion:** 2032-12
- **Final completion:** 2032-12
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880876, "A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04880876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*